Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Clinical trial NCT01125293 · TERMINATED
Trial details
- NCT number
- NCT01125293
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-04-01
- Primary completion
- 2013-12-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.